Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Agilent Names DePinho Thought Leader and More


Agilent Technologies said this week that it has awarded its Agilent Thought Leader Award to Ronald DePinho, an oncologist at the University of Texas MD Anderson Cancer Center.

The award provides funds for personnel and an Agilent 6550 iFunnel Q-TOF LC/MS system to support research. DePinho and his team are seeking to discover and characterize alterations in metabolic flux during tumor initiation and maintenance and to identify biomarkers for detecting pancreatic cancer.

Aushon Biosystems said this week it has appointed Thomas Mac Mahon to its board of directors.

Mac Mahon is a presiding director of Aristotle Holding and Express Scripts and was chairman of Laboratory Corporation of America from 1996 to 2009 and CEO and president from 1997 to 2006. Before that he was senior vice president at Hoffmann-La Roche and president of Roche Diagnostics.

Definiens has appointed Ralf Huss to be chief medical officer.

Huss has 20 years of training and experience in histopathology and cancer research, including serving as global head of histopathology and tissue biomarker at Roche Diagnostics, and he co-founded the biotech company APCETH.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.